Does NRXS pay a dividend and is it safe?

Neuraxis Inc. (NRXS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / NRXS / dividends

STXS (22) VANI (28) HYPR (38) OM (34) ⌘ Pro Terminal →

Neuraxis Inc. (NRXS) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.60 -7.43% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.50

Neuraxis Inc. (NRXS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $89.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRXS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NRXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neuraxis Inc. (NYSE: NRXS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.60 (-7.43% 1D, market cap $89.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXS ranks #569 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NRXS compare to STXS and VANI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NRXS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 84.2%, and ROIC of -35.0%. By comparison, STXS (Stereotaxis Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $86.4M) and VANI (Vivani Medical Inc.) posts a E grade (28/100 RQD, P/E 3.9x, ROIC -35.0%, cap $98.3M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRXS?

▼

Per NRXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933567), Neuraxis Inc. generated $3.6M in revenue (+32.9% YoY), -$7.8M in net income, and -$6.5M in free cash flow against $6.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.50 (-1.53%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRXS)Realized 20D OHLCV Swing Band: ±12.2%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY NRXS SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 1.88 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.50+20.3% Next Q

Q2 (-2Q)

Grade E$7.82-5.9% Next Q

Q3 (-1Q)

Grade E$7.36-10.3% Next Q

Current

Grade D-$6.60-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NRXS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NRXS currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.88) and Max Pain ($6.93) forces dealer call-delta covering toward $9.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NRXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRXS)

✓Walkthrough of NRXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.48%📐 HORIZONTAL RANGE

2026-11-03O $7.55H $7.55L $6.60C $6.60VOL 150.4K

RES: $8.43SUP: $4.29SMA50: $6.88SMA200: $6.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRXS Butterfly Map → + Track NRXS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRXS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRXS)

Health Care Rank #569 of 1015 ⚔️ STXS vs NRXS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRXS vs. STXS, VANI, HYPR, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuraxis Inc. (NRXS) ranks #569 by composite RQD confidence (36/100, grade D-) and #667 by equity capitalization ($89.5M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with NRXS at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRXS ACTIVE Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-7.43%	$89.5M	Benchmark Subject
STXS Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	+2.03%	$86.4M	/stxs-vs-nrxs →
VANI Vivani Medical Inc.	E	28/100	3.9x	—	-35.0%	0.00%	$98.3M	/vani-vs-nrxs →
HYPR Hyperfine Inc. (Class A)	D-	38/100	—	49.8%	-35.0%	+0.99%	$76.1M	/hypr-vs-nrxs →
OM Outset Medical Inc.	E	34/100	—	39.1%	-28.0%	-0.25%	$75.8M	/om-vs-nrxs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001933567 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuraxis Inc. (NRXS) reported GAAP revenue of $3.6M (+32.9% vs. FY2024 revenue of $2.7M , and +45.1% cumulative change since FY2023) , GAAP net income of -$7.8M, operating cash flow of -$6.4M, and free cash flow of -$6.5M (-5.5% YoY). On the balance sheet, NRXS closed FY2025 with $6.4M in total assets against $0 in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.6M	-$7.8M	-$6.4M	-$6.5M	$6.4M	—
FY2024 (FY)	2024-12-31	$2.7M	-$8.2M	-$6.1M	-$6.1M	$4.8M	—
FY2023 (FY)	2023-12-31	$2.5M	-$14.6M	-$6.7M	-$6.7M	—	—

3. NRXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NRXS compare to STXS and VANI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NRXS?

Where is NRXS trading relative to its 50-day, 200-day, and 52-week technical levels?

NRXS last traded at $6.60 (-7.43% on volume of 125,734 shares), positioning the stock -4.07% below its 50-day simple moving average ($6.88) and -1.35% below its 200-day simple moving average ($6.69). Across its 52-week range of $2.21 to $9.33, NRXS sits at the 61.7% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($5.79 to $7.41).

Direct Sub-Reports: NRXS RQD Cockpit NRXS 12M Forecast NRXS Earnings & Move NRXS Dividends & DRIP NRXS Insiders & 13F NRXS Whale Options NRXS Profit Sankey NRXS News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

NRXS — Neuraxis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuraxis Inc. (NRXS) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.60 (-7.43% 1D, market capitalization $89.5M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 84.2%, operating margin of -60.0%, and free cash flow yield of -6.82%.
Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.88, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neuraxis Inc. Is a NYSE-listed company classified in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It operates in this electromedical niche with a market capitalization of $0.1B. FY 2025 revenue was $3.6M, indicating a small revenue base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Neuraxis Inc. (NRXS) reported $3.6M in annual revenue (up from $2.7M in FY2024, +32.9% YoY) and -$7.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$14.6M net income) through FY2025, NRXS scaled operating cash flow to -$6.4M and free cash flow to -$6.5M, backed by $6.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.82% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $2.21 – $9.33 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Accordingly, no upstream or downstream dependencies or sector-correlation links are available in source data. A prospective investor should note that coverage expansions and reimbursement-related milestones in the news feed could create second-order effects on revenue scaling, but the graph does not map these to specific suppliers, customers, or peers.

Key Question #1: Can NRXS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $3.6M and free cash flow of -$6.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NRXS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuraxis Inc. (NRXS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NRXS Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 22h ago

Neuraxis declares common-stock dividend for Series B preferred, ~81,339 shares to be issued

TradingView report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

Yahoo Finance report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An ear-stimulating treatment for gut pain now has coverage reaching over 147 million people.

Stock Titan report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

Neuraxis CRO Carrico buys $1,587 in common stock By Investing.com

Investing.com India report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Neuraxis Inc. (NRXS) Jumps 18.53% to $7.74 as Shares Approach Key Resistance - Large Cap Trends

https://www.dars.gov.et/ report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Neuraxis CFO Timothy Henrichs buys $9,375 in company stock By Investing.com

Investing.com UK report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 4 Neuraxis Inc For: 8 October By Investing.com

Investing.com UK report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

NRXS Q2 2026 Earnings: Narrower Loss per Share Beats Consensus Estimate - EPS Revision Trend

https://www.dars.gov.et/ report covering Neuraxis Inc. (NRXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRXS Bull vs. Bear Conversation Board — What's Your Call at $6.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRXS 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $8.48 (+18.9%)

📌 Pinned Debate

Revenue grew from $2.5M in FY 2023 to $3.6M in FY 2025 while cash rose from $3.7M to $5.0M, and the whale/13F flow pillar scored 13 of

Don't sleep on NRXS's setup in Health Care. Revenue grew from $2.5M in FY 2023 to $3.6M in FY 2025 while cash rose from $3.7M to $5.0M, and the whale/13F flow pillar scored 13 of 20.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (36/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NRXS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $5.78 (-18.9%)

Spot @ $7.13

Operating margin of -60% and ROIC of -35% against negative free cash flow in every reported year leave the fundamental cash engine scor

Here is the bear case nobody on the bull side wants to address on NRXS: Operating margin of -60% and ROIC of -35% against negative free cash flow in every reported year leave the fundamental cash engine scoring only 5 of 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.